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Abstract 
SIRT1, an NAD-dependent histone/protein deacetylase, has classically been thought of as a 
nuclear protein. In this study, w e   d e m o n s t r a t e   t h a t   S I R T 1   i s   m a i n l y   l o c a l i z e d   i n   t h e   n u c l e u s   o f  
n o r m a l   c e l l s ,   b u t   i s   p r e d o m i n a n t l y   l o c a l i z e d   i n   t h e   c y t o p l a s m   o f   t h e   c a n c e r   /   t r a n s f o r m e d   c e l l s  
we tested. We found this predominant cytoplasmic localization of SIRT1 is regulated by 
elevated mitotic activity and PI3K/IGF-1R signaling in cancer cells. We show that aberrant 
cytoplasmic localization of SIRT1 is due to increased protein stability and is regulated by 
PI3K/IGF-1R signaling.   I n   a d d i t i o n ,   w e   d e t e r m i n e d   t h a t   S I R T 1   i s   r e q u i r e d   f o r   P I 3 K -mediated 
cancer cell growth. Our study represents the first identification that aberrant cytoplasm lo-
calization  is  one  of  the  specific  alternations  to  SIRT1  that  occur  in  cancer  cells,  and 
PI3K/IGF-1R signaling plays an important role in the regulation of cytoplasmic SIRT1 stability. 
Our findings suggest that the over-expressed cytoplasmic SIRT1 in cancer cells may greatly 
contribute to its cancer-specific function b y   w o r k i n g   d o w n s t r e a m   o f   t h e   P I 3 K / I G F -1R signaling 
pathway. 
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INTRODUCTION 
Silent i n f o r m a t i o n   r e g u l a t o r   1   ( S I R T 1 )   i s   a   n i c o-
tinamide  adenine  dinucleotide  (NAD)-dependent 
h i s t o n e   d e a c e t y l a s e   ( c l a s s   I I I   H D A C ) ,   w h i c h   h a s   b e e n  
reported to be a crucial regulator in the pathophysi-
ology of aging, metabolic disease and neurodegener-
ative  disorders  [1-6].  In  addition,  SIRT1  has  been 
shown to be a cancer cell-specific growth factor [7-10]. 
The knockdown of SIRT1 expression halts the growth 
of various tumor cell lines, but does  not  impact nor-
mal human epithelial cell growth [7-9].  
SIRT1  h a s   c l a s s i c a l l y   b e e n   t h o u g h t   o f   a s   a nuc-
lear  protein  that  functions  to  regulate  histones  and 
non-histone  substrates  with  its  deacetylase  activity 
[4-6,  11-16]. M a n y   f a c t o r s   i n   t h e   n u c l e u s   h a v e   b e e n  
identified as SIRT1 substrates, such as p53 [17], FOXO 
[18,  19],  E2F  [20],  HIC1  [21],  Rb  [22],  AR  [23]  and 
WRN [24, 25]. These SIRT1 nuclear substrates are in-
volved  in  various  biological  processes  including 
stress-induced apoptosis, cell senescence, cell growth 
and DNA repair. Recent evidence suggests, however, 
t h a t   S I R T 1   c a n   a l s o   l o c a l i z e   t o   t h e   c y t o p l a s m  such as 
in  murine  pancreatic  beta  cells  and  rat cardiomyo-
cytes [26-29]. I n   c a n c e r   c e l l s ,   S I R T 1   c y t o p l a s m i c   l o c a-
lization remains largely unidentified, and it is unclear 
if SIRT1 localization changes during carcinogenesis.  
In  this  study,  we  report for  the  first  time  that 
while  SIRT1  is  mainly  localized  in  the  nucleus  of 
normal / primary cells, it is predominantly localized 
i n   t h e   c y t o p l a s m   o f   c a n c e r  /  transformed cells. Not 
o n l y   h a v e   w e   o b s e r v e d   t h i s   l o c a l i z a t i o n   p a t t e r n   i n  
prostate cancer cell lines, but we have also seen this in 
l u n g   a n d   b r e a s t   c a n c e r   c e l l s ,   t r a n s f o r m e d   c e l l   l i n e s  
and prostate carcinoma tissues. We found that inhibi-
tion of PI3K/IGF-1R signaling or reduction of mitotic Int. J. Biol. Sci. 2010, 6 
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activity  in  cancer  cells  reduces  the  abundance  and 
protein stability of cytoplasmic SIRT1. Moreover, we 
show that SIRT1 is required for PI3K induced growth 
in  prostate  cancer  cells.  These  results  indicate  that 
aberrant cytoplasmic localization of SIRT1 is a cancer 
specific  alteration;  PI3K/IGF-1R  signaling  increases 
the stability of cytoplasmic SIRT1 and ultimately re-
sults in its aberrant cytoplasmic localization. Because 
SIRT1 is an important protein deacetylase with both 
histone  and  non-histone  substrates,  changes  in  its 
localization  will  greatly  affect  its  targets  and  will 
likely translate further into important functional con-
sequences for cell growth, survival and proliferation. 
O u r   f i n d i n g s   s u g g e s t   t h a t   t h e   over-expressed cytop-
lasmic SIRT1 in cancer cells may greatly contribute to 
its  cancer-specific  function  by working downstream 
of the PI3K/IGF-1R signaling pathway. 
MATERIALS AND METHODS  
Antibodies, plasmids and cell lines 
SIRT1 antibody (sc-74504,  sc-19857) and Lamin 
A/C  (sc-20681)  were  purchased  from  Santa  Cruz 
Biotechnology  (Santa  Cruz,  California).  α-Tubulin 
(T6074)  and  β-Actin  (A-1978)  were  purchased  from 
Sigma  Aldrich  (St.  Louis,  Missouri).  Anti-BrdU 
(NMM1645458) and anti-SIRT1 (07-131, 05-707) were 
purchased  from  Upstate-Millipore  (Billerica,  MA). 
SIRT1 antibody  (C05187) was  purchased  from  Epi-
tomics  (Burlingame,  CA).  And  anti-hSir2  antibody 
(856)  [17] i s   a   g i f t   f r o m   D r .   Roy  A.  Frye (Pittsburgh 
Veterans Administration Medical Center, Pittsburgh, 
PA  15240).  T h e   S I R T 1   R N A i   v e c t o r   (pSU-
PER.retro.puro-SIRT1)  was  generously  provided  by 
Dr. F. Picard (Laval University, Quebec, Canada). 
DU145,  PC3,  MCF-7, H460 were maintained in 
1x  DMEM  with 10% FBS. LNCaP, MRC5, BR3 and 
BR3neo cells were maintained in 1640 RPMI with 10% 
FBS. PZ-HPV-7 cells were maintained in Keratinocyte 
Serum-Free Medium (Invitrogen, catalog no. 10724) + 
Supplements  (Invitrogen,  catalog  no.  37000-015).  All 
cell lines were obtained from ATCC except the BR3 
c e l l   l i n e ,   w h i c h   w a s   a   g i f t   f r o m   Penny A. Jeggo (Uni-
v e r s i t y   o f   S u s s e x ,   E a s t   S u s s e x ,   B N 1   9 R Q ,   U K ) . Prostate 
cancer tissues and normal prostate tissues were pur-
chased from Cybrdi, Inc (Rockville, Maryland) 
Isolation of nuclear and cytoplasmic protein  
Nuclear and cytoplasmic proteins were isolated 
using  NE-PER Nuclear and Cytoplasmic Extraction 
Reagents  kit  and following the detailed instructions 
provided  (Pierce  Biotechnology).  Protease  inhibitor 
tablets (Roche Diagnostics)  and  the  phosphatase  in-
hibitors, 10mM sodium pyrophosphate (Fisher Scien-
tific)  and  100  μM  sodium  orthovanadate  (Fisher 
Scientific), w e r e   a d d e d   t o   t h e   C E R I   a n d   N E R   e x t r a c-
tion reagents prior to use.  
Immunoblot 
Cells  were  lysed  with  1%  Nonidet  P-40  lysis 
buffer (1% NP40, 150mm NaCl, 50mM Tris-HCl) with 
protease  inhibitor  (Roche  Diagnostics).  The  concen-
t r a t i o n   o f   c e l l   e x t r a c t   w a s   m e a s u r e d   b y   Bradford as-
say.  The  protein  samples  were  subsequently  sepa-
rated on an 8% SDS gel and analyzed with antibodies 
anti-SIRT1, Lamin A/C, β-Actin and α-Tubulin.  
Immunofluorescence Assay 
Cells (103-104)   w e r e   p l a t e d   i n   a   C h a m b e r   S l i d e  
and incubated for 24 hours. Cells were fixed with 4% 
paraformaldehyde, treated with 0.1% Sodium Citrate 
+ 0.1%Triton 100 and with Image-i T   F X   S i gnal  En-
hancer (Invitrogen). The cells were blocked with 3% 
BSA,  treated  with  anti-SIRT1  antibodies,  then  incu-
bated  with  Alexa  Fluor  secondary  antibodies  (Invi-
trogen) and stained with DAPI. 
BrdU  immunostainning  was  performed  with 
mouse anti-BrdU antibody. After being labeled with 
20uM  BrdU  for  12  hours,  standard  indirect  immu-
nofluorescence  was  performed  as  described  above, 
except  for  one  hour  DNase  I  treatment  before  the 
blocking step. Images were collected using a decon-
volution microscope (Nikon deconvolution wide-field 
Epifluorescence system). 
Establishment of stable SIRT1-knockdown cell 
lines  
The  pSUPER.retro.puro-SIRT1  or  the  pSU-
PER.retro vectors was  used  [30]. The Phoenix pack-
aging  cell  line  was  transfected  with  the  pSU-
PER.retro.puro-SIRT1  or  the  pSUPER.retro  vectors 
separately,  using  Lipofectamine  2000  (Invitrogen, 
Carlsbad, CA). After 48 hr,  the  medium  containing 
retrovirus was collected, filtered ,   t r e a t e d   w i t h   p o l y-
brene, and transferred to DU145, PC3, LNCaP, H460 
and  PZ-HPV-7  cell  cultures.  Infected  cells  were  se-
lected with puromycin for isolation of stably infected 
colonies.  
Cell viability assay 
Cells were plated at a density of 5x103 cells per 
well on 96-well p l a t e s   a n d   c u l t u r e d   f o r   2 4 h r ,   f o l l o w e d  
by treatment with Ly294002 (440202, CALBIOCHEM ) 
for  72hr.  Then  20  µl  MTS  (G3580,  Promega)  was 
added t o   t h e   m e d i u m   f o r   1   h ,   a n d   t h e   a b s o r b a n c e   w a s  
read at 490 nm in an Elisa plate reader. 
BrdU based cell proliferation assay  
2x104cells/well was seeded in a 96 well plate and 
BrdU (5mM) was added to each well for 24hr. The Int. J. Biol. Sci. 2010, 6 
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c e l l s   w e r e   f i x e d   a n d   s t a i n e d   w i t h   a n t i -BrdU antibody 
for 20hr at RT. Anti-mouse IgG HRP was added for 30 
min  and  100ul/well TMB peroxidase substrate was 
added for 30min. The integration of BrdU into the cell 
was determined at 450mM in the spectrophotometer 
m i c r o p l a t e   r e a d e r .   T h e   w e l l s   t h a t   d i d   n o t   r e c e i v e   c e l l s  
a n d   w e l l s   t h a t   c o n t a i n   c e l l s   b u t   d i d   n o t   r e c e i v e   a n y  
BrdU reagent were included as controls. The detailed 
p r o c e d u r e   c a n   b e   f o u n d   i n   t h e   B r d U   C e l l   P r o l i f e r a t i o n  
Assay (Cat# 2750) from Milipore (Billerica, MA) 
Real-Time RT-PCR 
 Total  cellular  RNA  was  isolated  using  Trizol 
reagent (Invitrogen Life Technologies, Carlsbad, CA) 
according  to  the  manufacturer’s  instructions.  A 
two-step RT-P C R   m e t h o d   w a s   e m p l o y e d   t o   s y n t h e s-
ize single-s t r a n d e d   c D N A   ( S u p e r S c r i p t   T M   I I I   F i r s t  
Strand kit, Invitrogen, 18080-051). Target genes were 
analyzed by real-time PCR using Applied Biosystems 
7500 Fast Real-Time PCR System with SYBR Green I 
dye (Applied Biosystems, 43091 5 5 ) .   T h e   p r i m e r s   u s e d  
were:  SIRT1  forward:  TAGTGACTGGACTCCA 
AGGCC,  SIRT1  reverse:  CAGTGTCATATCATCCA 
ACTCAGGT;  β-actin  forward:  GAGAAAATCTGG 
CACCACACC;  β-actin  reverse:  ATACCCCTCGTA 
GATGGGCAC.  PCR  reactions  were  performed  in 
triplicate.  
RESULTS 
SIRT1 is predominantly localized in the cytop-
lasm in cancer / transformed cells 
I n   o r d e r   t o   c l e a r l y   u n d e r s t a n d   t h e   l o c a l i z a t i o n  
p a t t e r n   o f   S I R T 1   i n   c a n c e r   cells,  we  performed  im-
munoblots combined with cell fractionation to ana-
lyze the localization of SIRT1. Lung, breast and pros-
tate cell lines, as well as tissues, were  analyzed.  The 
whole cell or  tissue lysates were separated into nuc-
lear  and  cytoplasmic  fractions,  and  immunoblots 
were  performed  with  anti-SIRT1  antibodies.  Unex-
pectedly,  we  found  that  SIRT1  (MW=120kd)  was 
predominantly localized in the cytoplasm, rather than 
in the nucleus of cancer cells lines including DU145, 
PC3, LNCaP and LNCaP-C4-2B prostate cancer cell 
lines, H460 lung cancer cells, MCF-7 breast cancer cell 
lines, and prostate cancer tissues (Figure 1A and data 
not  shown).  Fractionation  efficiency  was  confirmed 
by immunoblot with the α-tubulin antibody that re-
cognizes the protein in the cytoplasm, and the lamin 
A/C that binds the protein in the nucleus (Figure 1A). 
To ensure that this cytoplasmic  localization of SIRT1 
w a s   n o t   o c c u r r i n g   a s   a   r e s u l t   o f   a n t i b o d y   e p i t o p e   s p e-
cificity,  we  subsequently  performed  immunoblots 
with several other SIRT1 antibodies and similar loca-
lization patterns of SIRT1 were observed (Figure S1). 
I n   o r d e r   t o   f u r t h e r   c o n f i r m   t h e   s p e c i f i c i t y   o f   l o c a l i z e d  
cytoplasmic S I R T 1 ,   w e   s o u g h t   t o   d e t e r m i n e   i f   c y t o p-
lasmic SIRT1 could be specifically knocked down via 
RNA interference. Our results demonstrated that both 
nuclear  and  cytoplasmic  SIRT1  (MW=120kd)  levels 
are  greatly  reduced  by  RNA  interference  of  SIRT1 
(siSIRT1)  as  compared to vector-transfected  cells  (si-
Vector)  in  DU145,  PC3, LNCaP and H460 cell lines 
(Figure 1B and data not shown). 
We subsequently analyzed the localization pat-
terns of SIRT1 in normal cell lines and tissues.   I n   c o n-
trast to cancer cell lines and tissues,   w e   f o u n d   S I R T 1  
predominantly  localized  in  the  nucleus  of  normal 
cells, including the prostate cell line, PZ-HPV-7, nor-
mal prostate tissues, the normal lung cell line, MRC5 
(Figure 1C), and the normal human fibroblast cell line, 
BR3 (Figure 1D). These results indicate that the SIRT1 
localization pattern differs between cancer and  nor-
mal cells. SIRT1 is predominantly localized in the cy-
t o p l a s m   o f   c a n c e r   c e l l s   a n d   i n   t h e   n u c l e u s   o f   n o r m a l  
cells.  
In addition,  we  compared the localization pat-
terns of  SIRT1  in transformed and primary cells. We 
established a  transformed  and  immortalized  fibrob-
last cell line,  BR3neo,  through  transfection  of  SV40 
L a r g e   T   t o   a   n o r m a l   p r i m a r y   f i b r o b l a s t   c e l l  line, 1BR3 
[31].  As  shown  in  Fig.1D,  SIRT1  is  predominantly 
localized in the nucleus in BR3, the primary cell line, 
whereas it is predominantly loca l i z e d   i n   t h e   c y t o p-
l a s m   i n   t h e   B R 3 n e o   t r a n s f o r m e d   c e l l s .   T h e s e   r e s u l t s  
indicate  that  the  predominant  cytoplasmic localiza-
t i o n   o f   S I R T 1   i s   a l s o   a s s o c i a t e d   w i t h   c e l l   t r a n s f o r m a-
tion.  
The over-expression of SIRT1 in cancer cells is 
mainly attributed to the elevation of cytoplasmic 
SIRT1 
After finding SIRT1 predominantly localized to 
the cytoplasm of cancer cells, we subsequently asked 
whether  the  previously documented overexpression 
of SIRT1 in cancer cells and  tissues [32-36] is mainly 
attributed to increased cytoplasmic SIRT1. The levels 
o f   c y t o p l a s m i c   a n d   n u c l e a r   S I R T 1   i n   c a n c e r   a n d   n o r-
mal cells were compared. The results demonstrated 
that the cytoplasmic SIRT1 level is robustly elevated 
i n   c a n c e r   c e l l s   c o m p a r e d   t o   n o r m a l   c e l l s ,   w h e r e a s   t h e  
nuclear SIRT1 is only marginally increased in cancer 
cells, such as prostate cancer cell line DU145 versus 
normal  prostate  cell  PZ-HPV-7 and the transformed 
cell line BR3neo versus its parental normal cell BR3 
(Figure  1D).  Thus,  the  over-expression  o f   S I R T 1   i n  
c a n c e r   c e l l s   i s   m a i n l y   a t t r i b u t e d   t o   t h e   e l e v a t i o n   o f  
cytoplasmic SIRT1.  
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Fig.1. Localization patterns of S I R T 1   i n   c a n c e r   a n d   n o r m a l   c e l l s .   A. Cytoplasmic and nuclear fractions of DU145 
and PC3 cells and prostate cancer tissues were isolated, the concentration of nuclear and cytoplasmic protein was measured 
by Bradford assay, the same amount of nuclear and cytoplasmic protein was subjected to SDS gel, and immunoblots were 
performed with anti-SIRT1, α-tubulin and LaminA/C antibodies. B. Cytoplasmic and nuclear proteins were isolated from 
DU145 cells transfected with RNA interference of SIRT1 (siSIRT1) or vector control (siVector). Equal amounts of nuclear 
and cytoplasmic protein were loaded, and immunoblots were performed with the same antibodies used in Fig.1A. C. The 
nuclear and cytoplasmic fractions of normal prostate cell PZ-HPV-7, normal lung cell MRC5 and normal prostate tissues 
were prepared. The same amount of nuclear and cytoplasmic protein was loaded, and immunoblots were performed with 
the same antibodies as Fig.1A. D. The nuclear and cytoplasmic fractions of primary and transformed human fibroblast cells 
BR3 and BR3neo, normal prostate cell PZ-HPV-7 and prostate cancer cell line DU145 were prepared. Equal amounts of 
nuclear and cytoplasmic protein were loaded and immunoblots were performed with the same antibodies as Fig.1A.  
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Increased mitotic activity of cancer cells pro-
motes cytoplasmic localization of SIRT1  
Because  cancer  cells  present  a  higher  level  of 
mitotic activity compared to normal cells, the finding 
that cytoplasmic SIRT1 is robustly increased in cancer 
cells seems to suggest a correlation between the SIRT1 
localization  and  the  mitotic  activity  of  cancer  cells. 
I n d e e d ,   t h e   d o u b l i n g   t i m e   o f   a l l   o f   o u r   a n a l y z e d   c a n-
cer cells with predominant cytoplasmic localization of 
SIRT1 including DU145, PC3, H460 and BR3neo cells 
is less than 8   h o u r s , which contrasts with the doubling 
t i m e   o f   4   t o   8   d a y s  f o r   a l l   t h e   n o r m a l   c e l l s with pre-
dominant  nuclear  localization  of  SIRT1  including 
PZ-HPV-7 ,   M R C 5   a n d   B R 3   c e l l s   ( d a t a   n o t   s h o w n ) . In 
order  to  understand  whether  the  increased  mitotic 
a c t i v i t y   o f   c a n c e r   c e l l s   r e g u l a t e s   t h e   p r e d o m i n a n t   cy-
toplasmic localization of SIRT1, we treated the cells 
with  and  w i t h o u t   s e r u m   o r   h y d r o x y u r e a ,   w h i c h  
b l o c k s   t h e   c e l l   c y c l e ,   t o   s t u d y   i f   r e d u c i n g   /   b l o c k i n g  
cancer cell proliferation / division would affect SIRT1 
localization. Immunofluorescence assays showed that 
SIRT1 is localized in both the nucleus and cytoplasm 
under  normal culture conditions  (10%  FBS)  (Figure 
2A).  However,  after  serum  depletion,  we  observed 
S I R T 1   w a s   l a r g e l y   d i m i n i s h e d   f r o m   t h e   c y t o p l a s m  
(Figure  2B).  When  the  serum  was  replaced  in  the 
starved cells for 24hr, the depleted cytoplasmic SIRT1 
exhibited  restoration  (Figure  2C).  Hydroxyurea 
treatment, specifically the S phase and cell division, 
ha d   a n   e f f e c t   s i m i l a r   t o   t h a t   o f   t h e   s e r u m   d e p l e t i o n  
treatment (Figure 2D). These results suggest that in-
creased mitotic activity or growth signaling promotes 
the cytoplasmic localization of SIRT1, and conversely, 
the  reduced  mitotic  activity  or  reduced  growth  sig-
naling decreased cytoplasmic SIRT1.  
Protein abundance rather than the translocation 
plays a dominant role in SIRT1 cytoplasm loca-
lization 
S i n c e   m u r i n e   S I R T 1 ,   w h i c h   h a s   8 4 %   h o m o l o g y  
w i t h   h u m a n   S I R T 1 ,   h a s   b e e n   r e p o r t e d   t o   b e   a   n u c-
leo-cytoplasmic shuttling protein mediated by a NLS 
and  NES-dependent  mechanism  [37],  we  asked 
whether the decreased cytoplasmic SIRT1 induced by 
serum depletion and hydroxyurea treatment in cancer 
cells  had  translocated  to  the  nucleus.  Immunoblot 
analysis was performed with the fractionated nuclear 
and  cytoplasmic  proteins,  which  were  treated  with 
s e r u m   d e p l e t i o n   o r   h y d r o x y u r e a .   T h e   r e s u l t s   s h o w e d  
no increase in nuclear SIRT1 when cytoplasmic SIRT1 
is diminished by starvation (Figure 3A) or hydroxyu-
rea  treatment  (data  not  shown).  In  addition,  we 
treated the cells with leptomycin B (LMB), an inhibitor 
o f   t h e   N E S -dependent  nuclear  exporter,  and  found 
SIRT1 in cancer cells neither accumulated in the nuc-
leus nor diminished from the cytoplasm in the pres-
ence of LMB (Figure 3B). Additionally, we treated the 
starved  cells  with  serum  with  or  without  LMB  and 
found  that  LMB  treatment  did  not  affect  the  cytop-
lasmic SIRT1 restoration by serum replacement (Fig-
ure  3C). These results suggest that predominant cy-
toplasmic localization induced by mitotic activity or 
growth signals is not due to SIRT1 translocation, but 
rather to the change in the abundance of cytoplasmic 
SIRT1.  
PI3K/IGF-1R signaling regulates protein stability 
of cytoplasmic SIRT1 
In  order  to  identify  which  signaling  pathway 
may regulate the abundance of cytoplasmic SIRT1, we 
treated  the  cells  with  various  kinase  inhibitors  in-
cluding inhibitors Ly294002 and AG1024 for PI3K and 
IGF-1R respectively, as well as Rottlerin, a PKC inhi-
bitor and determined their effect on the abundance of 
cytoplasmic  SIRT1.  We  found  that  treatment  with 
Ly294002 and AG1024 reduced levels of cytoplasmic 
SIRT1 ,   a s   d e t e r m i n e d by immunoblot (F i g u r e   4 A).   T h e  
quantitative  RT-PCR  analysis  shows  no  obvious 
c h a n g e   i n   S I R T 1   m R N A   l e v e l s   i n   r e s p o n s e   t o   P I 3 K  
and  IGF-1R inhibition (Figure 4B). We subsequently 
wanted to determine whether the reduced abundance 
o f   c y t o p l a s m i c   S I R T 1   w a s   d u e   t o   a   protein  stability 
change. T h e   c y t o p l a s m i c   a n d   n u c l e a r   S I R T 1   w e r e   i s o-
l a t e d   f r o m   t h e   c a n c e r   c e l l s ,   a n d   e i t h e r   treated  with 
Ly294002 or AG1024 or left untreated and then com-
bined  with  cycloheximide  (CHX)  to  inhibit  protein 
synthesis,  The  SIRT1  protein  level  was  then  deter-
mined by immunoblotting. The  results  showed  that 
inhibition  of  either  IGF-1 R   o r   P I 3 K   kinase  activity 
reduced cytoplasmic SIRT1  stability  (Figure  4C) but 
h a d   n o   e f f e c t   o n   t h e   s t a b i l i t y   o f   n u c l e a r   S I R T 1   ( d a t a  
not  shown),  as  the  half-life  of  cytoplasmic  SIRT1 
c h a n g e d   f r o m   1 1 h r   t o   6 h r   f o r   I G F -1R inhibition, and 
11hr to 4hr for PI3K inhibition (Figure 4C). These re-
sults  suggest  that  PI3K/IGF-1R  signaling  regulates 
the protein stability of cytoplasmic SIRT1. 
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Fig.2. Mitotic signaling regulates cytoplasmic localization of SIRT1. DU145 cells were cultured in the chamber 
slide with DMEM+10% FBS. The immunofluorescence was performed with anti-SIRT1 antibody (sc 74504, Santa Cruz 
1:1000, RT 1hr) and Alexa Fluor 488 anti-mouse (Invitrogen, 1:20 0 ,   R T   1 h r ) .   N u c l e a r   p r o t e i n   w a s   s t a i n e d   w i t h   D A P I  
(1:10,000). A. DU145 cells were cultured with DMEM+10% FBS. B. The DU145 cells that were cultured in the DMEM+10% 
FBS were shifted to serum-free DMEM for 48 hr. C. After culturing the DU145 cells in serum-free medium for 48hr, the 
m e d i u m   w a s   replaced with D M E M + 1 0 %   F B S   f o r   24hr. D. DU145 cells that were cultured in DMEM+10%FBS were treated 
with hydroxyurea for 24 hr.  Int. J. Biol. Sci. 2010, 6 
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Fig.3. Translocation does not play a dominant role in SIRT1 cytoplasm localization. A. The DU145 cells that 
were cultured in the DMEM+10% FBS were shifted to serum-free DMEM for 24 hr. The nuclear and cytoplasmic proteins 
were fractionated and equal amounts of nuclear and cytoplasmic protein were loaded, and immunoblots were performed 
with anti-SIRT1, Lamin A/C and tubulin antibodies. B. The DU145 cells were treated with either vehicle or 10nM LMB for 
two hours. The nuclear and cytoplasmic proteins were fractionated and equal amounts of nuclear and cytoplasmic protein 
were loaded and immunoblots were performed with anti-SIRT1, Lamin A/C and tubulin antibodies. C. T h e   D U 1 4 5   c e l l s   t h a t  
were cultured in the serum-free DMEM were shifted to DMEM+10% FBS with or without LMB for 2hr. The nuclear and 
cytoplasmic proteins were fractionated and the same amounts of nuclear and cytoplasmic protein were loaded and im-
munoblots were performed with anti-SIRT1, Lamin A/C and tubulin antibodies. Int. J. Biol. Sci. 2010, 6 
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Fig.4. PI3K and IGF-1R regulates the protein stability of cytoplasmic SIRT1. A. DU145 cells were treated with 
or without AG1024 (4µM) (left panel)   o r   Ly294002 (20µM) (right panel) for 12hr. The nuclear and cytoplasmic proteins 
were prepared and equal amounts of nuclear and cytoplasmic protein were loaded to SDS gel. The immunoblot was per-
formed with anti-SIRT1, tubulin and LaminA/C antibodies. B. Transcript levels of SIRT1 was measured by quantitative 
RT-P C R   a n a l y s i s   o f   R N A   e x t r a c t e d   f r o m   t h e   c e l l s  treated with or without AG1024 (4µM) or Ly294002 (20µM) for 12hr. 
Transcript levels are expressed relative to β-actin transcripts. C. DU145 cells were pretreated with or without AG1024 
(4µM) (left panel) or Ly294002 (20µM) (right panel) for 30minutes, then treated with cycloheximide (10μg/ml). The 
nuclear and cytoplasmic proteins were isolated after treatment with cycloheximide for 0, 5 and 15h r   a n d   t h e   same amounts 
of nuclear and cytoplasmic p r o t e i n s   w e r e   s u b j e c t e d   t o   S D S   g e l .   T h e   i m m u n o b l o t   w a s   p e r f o r m e d   w i t h   a n t i -SIRT1 and an-
ti-tubulin antibodies.  
 
 
 
SIRT1 functions downstream of PI3K and regu-
lates prostate cancer cell growth 
PI3K and IGF-1 R   h a v e   b e e n   r e p o r t e d   t o   p l a y   a n  
important  role  in  prostate  cancer  cell  growth  and 
survival  [38,  39].  We  found that PI3K can regulate 
cytoplasmic  SIRT1  stability,  suggesting  that  SIRT1 
may play a role in PI3K-mediated cancer cell growth. 
We therefore firstly performed an MTS assay to study 
t h e   e f f e c t   o f   S I R T 1   k n o c k d o w n   o n  PI3K inhibitor in-
duced  cell  growth  arrest.   T h e   r e s u l t s   s h o w e d   t h a t  
Ly294002  treatment  induced  great  inhibition  in 
SIRT1-overexpressed  prostate  cancer  cells,  induced 
50% growth inhibition in PC3 cells and 45% in LNCaP 
cells with wt SIRT1, while inducing only a 20% inhi-
bition in SIRT1  knockdown  cells  (Figure  5A  &  5B). Int. J. Biol. Sci. 2010, 6 
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Fig.5.  SIRT1  silencing  attenuates  PI3K  inhibition-mediated  prostate cancer  cell  growth arrest.  Prostate 
cancer cell lines PC3 (5A)   a n d   L N C a P   ( 5B) in which SIRT1 had been knocked down by siRNA expression (siSIRT1) or 
empty-vector-transfected cells (siVector) were exposed to the Ly292002 (20µM).Viable cells were quantitated at 72hr by 
MTS assay. The error bars represent the SEM. The SIRT1 knockdown efficiency was shown in 5A and 5B lower panel. C. Int. J. Biol. Sci. 2010, 6 
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The SIRT1 knockdown (siSIRT1) and empty-vector control (siVector) PC3 cells were treated with or without Ly292002 
(20µM) for 24hr, then exposed to the BrdU (20uM) for another 24hr. The immunostaining was performed with anti-BrdU 
antibody (NMM1645458) and anti-mouse 594 secondary antibody. The images were taken with Nikon deconvolution 
wide-field Epifluorescence system. 100x. D. The SIRT1 knockdown (siSIRT1) and empty-vector control (siVector) PC3 cells 
were treated with or without Ly292002 (20µM) for 24hr, then exposed to the BrdU (4uM) for 24hr. The cells were fixed, 
immunostainned with anti-BrdU antibody and peroxidase conjugate secondary antibody; the peroxidase substrate was 
added and plates were read at 450nM. The error bars represent the SEM. E. MTS analysis for normal prostate cells 
PZ-HPV-7 cells. The experiment conditions are the same as 5A and 5B. The SIRT1 knockdown efficiency was shown in 5E 
lower panel. 
 
Similar results were seen using Brdu immunos-
taining (Figure 5C) and BrdU-based  proliferation  as-
say (Figure 5D). The results show that PI3K inhibition 
r e s u l t   i n   m u c h   m o r e   r e d u c t i o n   o f   B r d u   i n t e g r a t i o n   t o  
t h e   c e l l s   i n   S I R T 1   w i l d   t y p e   c e l l s   t h a n   i n   S I R T 1  
knockdown  cells  (Figure  5C  &  5D).  However,  in 
normal prostate PZ-HPV-7 cells in which SIRT1 ex-
pression is lower and is predominantly in the nucleus, 
PI3K inhibition induce little growth arrest for both 
S I R T 1   w t   a n d   S I R T 1   k n o c k d o w n   c e l l s   ( F i g u r e   5 E ) .  
These  results  suggest  that  SIRT1  is  an  important 
downstream target o f   P I 3 K   i n   t h e   r e g u l a t i o n   o f   c a n c e r  
cell  growth and survival, and overexpressed cytop-
lasmic SIRT1 in cancer cells may play an important 
role in this regulation. 
DISCUSSION 
I n   t h i s   s t u d y   w e   demonstrated  that  SIRT1  is 
predominantly  localized  in  t h e   c y t o p l a s m   o f   c a n c e r  
cells, while in normal cells, SIRT1 is predominantly 
localized in the nucleus. SIRT1 cytoplasmic localiza-
tion  in  cancer  cells  is  largely  unidentified  and  it  is 
unclear if SIRT1 localization has any changes during 
carcinogenesis. Our study represents the first identi-
fication that aberrant cytoplasmic localization is  one 
of  the  cancer-specific  alternations  to  SIRT1.  This 
f i n d i n g   m a y   s u g g e s t   a   n e w   m e c h a n i s m   f o r   S I R T 1  
function  as  a  cancer-specific survival factor  by  tar-
geting cytoplasmic proteins.  
In contrast to its well-described role in the nuc-
leus, t h e   f u n c t i o n   o f   c y t o p l a s m i c   S I R T 1   is largely un-
known. However, recent findings that some cytoplas-
m i c   p r o t e i n s   c a n   b e   d e a c e t y l a t e d   b y   S I R T 1   p r o v i d e  
important  insights  into  the  function  of  cytoplasmic 
SIRT1. SIRT1 was found to enhance IGF-1 signaling 
by deacetylating ISH-2 ,   w h i c h   i s   a   c y t o p l a s m i c   p r o t e i n  
[27].  SIRT1  also  deacetylates  cytoplasmic  cortactin 
and promotes cancer cell migration [40]. In addition, 
S I R T 1   w a s   f o u n d   t o   p r o m o t e   t h e   a c t i v a t i o n   o f   c y t o p-
lasmic kinases, including AMPK, Ras-MAPK, Erk and 
S6K1 [8,  41,  42].  Furthermore,  SIRT1  was  shown  to 
regulate nucleo-cytoplasmic shuttling of transcription 
factors,  including  FOXO3a,  FOXO1,  and  PGC-1 
[43-47].  Because  many  known  SIRT1  substrates,  in-
c l u d i n g   p 5 3   a n d   N F-κB,  also  shuttle  between  the 
n u c l e u s   a n d   c y t o p l a s m ,   S I R T 1   c o u l d   r e g u l a t e   t h e i r  
function via cytoplasmic deacetylase activity. Recent 
study  show  that  cytoplasmic  SIRT1  can  promote 
nerve  growth  factor  (NGF)-induced  neurite  out-
growth  [48].  I n   a d d i t i o n ,   w e   f o u n d   t h a t   S I R T 1   c a n  
form a complex with E-cadherin in the cytoplasm and 
regulate cell-cell adhesion (unpublished data). These 
results provide support for the association of cytop-
lasmic  SIRT1  with  kinase  signaling,  nuc-
leo-cytoplasmic shuttling of the transcription factors, 
and with the proteins involved in cell adhesion and 
m i g r a t i o n .   S I R T 1   m a y   n o w   p r o v e   t o   b e   m o r e   m u l t i f a-
c e t e d   i n   f u n c t i o n   d u e   t o   its newly discovered predo-
minant  cytoplasmic localization,  which  may  play  a 
c r i t i c a l   r o l e   i n   c a n c e r   c e l l   d e v e l o p m e n t   a n d   p r o g r e s-
sion by targeting cytoplasmic substrates. 
In this paper we also elucidated the regulation of 
SIRT1 predominant cytoplasmic localization in cancer 
cells.  Ectopically  expressed  murine  SIRT1  has  been 
reported  as a nucleocytoplasmic  shuttle  protein  me-
diated by a NLS and NES-dependent mechanism [37]. 
However in human cancer cells, our results show that 
the nucleocytoplasmic shuttle d o e s   n o t   s e e m   t o   p l a y   a  
significant role in the regulation of increased cytop-
lasmic localization of SIRT1. Although we cannot ex-
clude  that  there  may  exist  translocation  for  small 
a m o u n t   o f   S I R T 1   i n   t h e   c ancer  cells,  the  nuc-
lear-cytoplasm  shuttle  is  not  a  major  mechanism in 
the regulation of cytoplasmic localization of SIRT1 in 
c a n c e r   c e l l s ,   a s   t h e r e   i s   n o   o b v i o u s   c h a n g e   i n   t h e   n u c-
lear SIRT1 level while cytoplasmic SIRT1 is altered. 
Instead, we found that PI3K/IGF-1R signaling regu-
lates  cytoplasmic  SIRT1  stability  and  abundance, 
which  suggests  the  PI3K/IGF-1R-mediated  cytop-
lasmic SIRT1 stability plays a dominant role in the 
regulation  of  aberrant  cytoplasm  localization.  The 
elevated SIRT1 protein levels in  cancer cells may re-
flect  abnormal  stabilization  induced  by  overactive 
PI3K/IGF-1R signaling.  
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Fig.S1. SIRT1 localization determined by both Immunofluorescence and immunobolt analysis. DU145 cells 
were cultured in the chamber slide with DMEM+10% FBS for the immunoflurorescence analysis (left panel). A. Anti-SIRT1 Int. J. Biol. Sci. 2010, 6 
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(C05187, Epitomics, 1:100, RT 1hr) and Alexa Fluor 488 goat anti-rabbit (Invitrogen, 200x, RT 1hr). B. Anti-hSir2 (856, 
1:500, RT 1hr) and Alexa Fluor 488 goat anti-rabbit (Invitrogen, 200x, RT 1hr). C. Anti-S I R T 1   ( SC-19857, Santa Cruz, 1:50. 
RT 1hr) and Alexa Fluor 546 donkey anti-goat (Invitrogen, 100x, RT 1hr). D. Anti-SIRT1 (07-131, Milipore, 1:50, RT 1hr) 
and Alexa Fluor 488 goat anti-rabbit (Invitrogen, 200x, RT 1hr). E. Anti-SIRT1 (sc-74504, Santa Cruz, 1:1000, RT 1hr) and 
Alexa Fluor 488 goat anti-mouse (Invitrogen, 200x, RT 1hr). F. Anti-S I R T 1   ( 05-707, upstate, 1:1000, RT 1hr) and Alexa Fluor 
594 goat anti-mouse (Invitrogen, 100x, RT 1hr). Cytoplasmic and nuclear fractions of DU145 cells were isolated and same 
amount of nuclear and cytoplasmic protein were subjected to SDS gels, and immunoblots were performed (right panel). 
A. Anti-SIRT1 (C05187, Epitomics, 1:500, RT 1hr). B. Anti-hSir2 (856, 1:1000, RT 1hr). C. Anti-SIRT1 (SC-19857, Santa 
Cruz, 1:200, 4
oC   O / N ) .   D. Anti-S I R T 1   ( 0 7 -131, Milipore, 1:500, 4
oC   O / N ). E. Anti-S I R T 1   ( s c -74504, Santa Cruz, 1:1000, RT 
1hr). F. Anti-SIRT1 (05-707, upstate, 1:1000, RT 1hr). 
 
 
Activated phosphoinositide 3-kinase (PI3K) is an 
important signaling molecule and acts as a key sur-
vival factor involved in the control of cell prolifera-
tion, apoptosis and oncogenesis [49]. Our results show 
that SIRT1  is  required  for  PI3K mediated  cancer  cell 
growth. The tumor suppressor PTEN is an inhibitor of 
PI3K and its loss or mutation has been associated with 
many  different  types  of  cancer;  in  the  absence  of 
PTEN, PI3K is constitutively activated and strongly 
inhibits  apoptosis  and  promotes  cell  survival  and 
proliferation  [39,  50].  Interestingly,  SIRT1  has  been 
shown to deactivate PTEN by deacetylation [51] and 
our results show that SIRT1 can be regulated by PI3K. 
It seems that there could be a positive feedback loop 
i n   t h e   c e l l   w h e r e b y   S I R T 1   i s   a   d o w n s t r e a m   t a r g e t   o f  
P I 3 K   s i g n a l i n g ,   w h i c h   m a y   s e q u e s t e r   S I R T 1   i n   t h e  
cytoplasm  to  deacetylate  PTEN  and  act  on  other 
non-histone  substrates  regulating  cell  growth  and 
s u r v i v a l .   I n d e e d   w e   f o u n d   S I R T 1   i s   r e q u i r e d   f o r   P I 3 K  
m e d i a t e d   c e l l   g r o w t h   i n   p r o s t a t e   c a n c e r   c e l l s   i n   w h i c h  
cytoplasmic  SIRT1  is  overexpressed,  but  inhibiting 
P I 3 K   i n   t h e   S I R T 1   d e f i c i e n t   c e l l s ,   o r   n o r m a l   p r o s t a t e  
c e l l s   i n   w h i c h   S I R T 1   e x p r e s s i o n   i s   l o w e r   a n d   i s   p r e-
dominantly  in  the  nucleus,  produces  a  much  lower 
p e r c e n t a g e   o f   g r o w t h   i n h i b i t i o n   ( F i g u r e   5 ) .   T h e s e   r e-
sults suggest that overexpressed cytoplasmic SIRT1 in 
cancer cells may be an important downstream target 
o f   P I 3 K   i n   t h e   r e g u l a t i o n   o f   p r o s t a t e   c a n c e r   c e l l  
growth and survival. However, further investigation 
is  needed  to  elucidate  the  detailed  mechanism  by 
which  cytoplasmic  SIRT1  is  involved  in 
P13K-mediated cell growth.  
Finally, i n   t h i s   s t u d y   w e   have clarified the cause 
of  the  controversial  report  for  SIRT1  localization  in 
cancer cells [13, 26, 28, 34].   D u e   t o   t h e   f a c t   t h a t   p u b-
lished data for SIRT1 localization is mainly generated 
from immunofluorescence analysis, we performed an 
immunofluorescence  assay  with  the  most  available 
SIRT1 antibodies to study whether antibody specific-
ity played a role in the controversial results. When we 
stained the same cells with a different anti-SIRT1  an-
tibody,  the  immunofluorescence  results  show  that 
while  some  antibodies  only  stain  nuclear  SIRT1 
(C05187 Epitomics) [36],   o t h e r s were either specific for 
cytoplasmic SIRT1 (05-707 upstate) [26] or recognized 
b o t h   n u c l e a r   a n d   c y t o p l a s m i c   S I R T 1   f o r m s   (   8 5 6   [17, 
52],  sc-74504,  and  SC-19857  (Santa  Cruz)  and 
07-131(milipore) (Figure S1). This data suggests that 
antibody  specific  epitopes  play  a  dominant  role  in 
determining if SIRT1 is localized in the nucleus or 
cytoplasm  while  using  the  immunofluorescence  as-
s a y ,   a n d   m a y   e x p l a i n   t h e   c o n t r o v e r s i a l   r e p o r t s   a b o u t  
SIRT1 localization. In order to eliminate the antibody 
specificity  issues  produce d   i n   t h e   i m m u n o f l u o r e s-
cence  experiments,  we  performed  an  immunoblot 
combined with nuclear-cytoplasmic SIRT1 fractiona-
tion to determine SIRT1 localization. All tested anti-
bodies  in  the  immunoblot  assays  have  shown  that 
S I R T 1   i s   p r e d o m i n a n t l y   l o c a l i z e d   i n   t he  cytoplasm 
regardless of whether or not the antibody in the im-
munofluorescence  assay  recognized  only  nuclear 
S I R T 1 ,   o n l y   t h e   c y t o p l a s m i c   S I R T 1 ,   o r   b o t h   t h e  nuclear 
and cytoplasmic SIRT1 (Figure S1 ) .   T h u s ,   t h e   i m m u-
noblot method can overcome the antibody specificity 
issues that arise in immunofluorescence assays. It is 
unclear why the SIRT1 antibody has such a dramatic 
effect in recognizing nuclear or cytoplasmic SIRT1 in 
immufluorescence. SIRT1 may form some structure or 
conformation with other proteins or organelles,  the-
r e b y   h i d i n g   t h e   i s o t o p e   a n d   m a k i n g   r e c o g n i t i o n   m o r e  
d i f f i c u l t   b y   s o m e   a n t i b o d i e s .   I t   i s   a l s o   p o s s i b l e   t h a t  
some SIRT1 antibodies may have non-specific recog-
n i t i o n   f o r   t h e   n u c l e a r   p r o t e i n s .   T h e r e f o r e ,   e x t r a   c a u-
tion should be used when interpreting the immunof-
lurescence or IHC results regarding SIRT1 localization 
or expression. The nuclear and cytoplasmic fractiona-
tion combined with immunoblot with SIRT1 antibody 
is a good way to study SIRT1 localization.  
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